Key Requirements To Ensure Patient Safety In The Development And Production Of Viral Vaccines

COVID-19 has drawn attention to the patient safety aspects of developing and manufacturing viral vaccines. This interview with with Renaud Chollet, Ph.D. and Danny Galbraith, Ph.D. gives insight into the issues and obstacles faced by pharmaceutical companies, the current regulatory framework, and what Merck is doing to prepare itself and its customers for the inevitable next outbreak requiring the speedy development of a vaccine as well as streamlined and fast, but also safe, manufacture.